Orphazyme's newly appointed CEO Christophe Bourdon certainly does not lack ambition. Within the next ten years, he sees potential for turning Orphazyme into the new Genmab – but with a focus on rare diseases, according to Danish newspaper Børsen.
Before reaching this point, however, he plans to start remedying the disappointment which the company recently had in a clinical trial for the muscle-wasting disease Inclusion Body Myositis (IBM), which caused the firm's share price to plummet.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Director Global Engineering 
Scientific Writer 
Cell Culture Scientist/Senior Scientist 
Production Director 
Industrial Designer- Design Engineer 
IRT Manager, Clinical Drug Supply 
Laboratory technician for process development and clinical manufacturing 
Nordic Medical Affairs Manager 
Clinical Trial Administrator 
(Senior) Drug Substance Specialist 
Account Manager 
Senior Project Manager (GMP - Life Science) 
Clinical Trial Manager for development of in vitro diagnostics 
Client Talent Acquisition Specialist 
Senior Chemical Safety Advisor 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office